2026 Q3 -tulosraportti
Vain PDF
112 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,44%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 11.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·19 t sittenGood momentum the last couple of months.
JAAA TAAARRRK ! Chemometec will never ever go below 8,7 billion in value again 🕺💪🏻 👻
23 t sitten
I think Chemm should explain to the market what it means to be a preferred partner with Roche and Tucan. It's an endorsement of Chemm's technology by very big players and opens the way for great future growth. I would like to get fundamental Invest's information confirmed that Chemm has made a sales agreement with Roche. Derived from info about 20% royalty.
·1 päivä sittenThere are some interesting posts about chemometec on the stock debate site Proinvestor.com. Here, the track with tecan is seen as a new strategic point, which they believe is overlooked by the market. How much there is to it, I find difficult to assess, but it sounds exciting. It would be interesting if someone with insight had comments on this in this chat.
ChemoMetec and Roche Diagnostics have now entered into a formal agreement, which specifically includes the development of a connection kit between Roche Cedex Bio Analyzer and ChemoMetec's Xcytomatic 30 (XM30) as well as the subsequent commercialization. The important part of the agreement: It is especially these three things that I find interesting: 1. Roche designs the connection kit Roche is responsible for design as well as verification & validation. 2. They will actively market the solution together Roche and ChemoMetec have committed to a joint go-to-market strategy. They will actively co-promote the combined solution to both existing and potential customers. 3. Both retain their own sales channels Roche continues to sell Cedex Bio. ChemoMetec continues to sell XM30. This means that the agreement is not just about integration — it attempts to create a unified commercial workflow where both companies can achieve more sales. In my assessment, this is significantly more interesting than an ordinary technical integration. The potential value chain becomes: Roche Cedex Bio + ChemoMetec XM30 ↓ integrated hardware/software ↓ validated solution ↓ joint go-to-market ↓ Roche + ChemoMetec expose the solution to their existing pharma/biotech customers ↓ more XM30 installations ↓ more recurring consumables So a Roche-driven acceleration of XM30 installations can have a multiplier effect: More instruments → larger installed base → more recurring consumables → higher and more predictable revenue. And when Roche simultaneously actively co-promotes the solution, ChemoMetec gains access to a sales engine that is enormously much larger than ChemoMetec's own organization.
·1 päivä sittenIt looks like there's a lot of resistance when it approaches 500. I think it will gain momentum when it breaks through.
Probably just a matter of short time before 500 is broken :) SEB's hold recommendation does not seem to stop the upward trend :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
Vain PDF
112 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,44%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 t sittenGood momentum the last couple of months.JAAA TAAARRRK ! Chemometec will never ever go below 8,7 billion in value again 🕺💪🏻 👻
- 23 t sittenI think Chemm should explain to the market what it means to be a preferred partner with Roche and Tucan. It's an endorsement of Chemm's technology by very big players and opens the way for great future growth. I would like to get fundamental Invest's information confirmed that Chemm has made a sales agreement with Roche. Derived from info about 20% royalty.
- ·1 päivä sittenThere are some interesting posts about chemometec on the stock debate site Proinvestor.com. Here, the track with tecan is seen as a new strategic point, which they believe is overlooked by the market. How much there is to it, I find difficult to assess, but it sounds exciting. It would be interesting if someone with insight had comments on this in this chat.ChemoMetec and Roche Diagnostics have now entered into a formal agreement, which specifically includes the development of a connection kit between Roche Cedex Bio Analyzer and ChemoMetec's Xcytomatic 30 (XM30) as well as the subsequent commercialization. The important part of the agreement: It is especially these three things that I find interesting: 1. Roche designs the connection kit Roche is responsible for design as well as verification & validation. 2. They will actively market the solution together Roche and ChemoMetec have committed to a joint go-to-market strategy. They will actively co-promote the combined solution to both existing and potential customers. 3. Both retain their own sales channels Roche continues to sell Cedex Bio. ChemoMetec continues to sell XM30. This means that the agreement is not just about integration — it attempts to create a unified commercial workflow where both companies can achieve more sales. In my assessment, this is significantly more interesting than an ordinary technical integration. The potential value chain becomes: Roche Cedex Bio + ChemoMetec XM30 ↓ integrated hardware/software ↓ validated solution ↓ joint go-to-market ↓ Roche + ChemoMetec expose the solution to their existing pharma/biotech customers ↓ more XM30 installations ↓ more recurring consumables So a Roche-driven acceleration of XM30 installations can have a multiplier effect: More instruments → larger installed base → more recurring consumables → higher and more predictable revenue. And when Roche simultaneously actively co-promotes the solution, ChemoMetec gains access to a sales engine that is enormously much larger than ChemoMetec's own organization.
- ·1 päivä sittenIt looks like there's a lot of resistance when it approaches 500. I think it will gain momentum when it breaks through.Probably just a matter of short time before 500 is broken :) SEB's hold recommendation does not seem to stop the upward trend :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 11.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
2026 Q3 -tulosraportti
Vain PDF
112 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 11.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
7,00 DKK/osake
Viimeisin osinko
1,44%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 t sittenGood momentum the last couple of months.JAAA TAAARRRK ! Chemometec will never ever go below 8,7 billion in value again 🕺💪🏻 👻
- 23 t sittenI think Chemm should explain to the market what it means to be a preferred partner with Roche and Tucan. It's an endorsement of Chemm's technology by very big players and opens the way for great future growth. I would like to get fundamental Invest's information confirmed that Chemm has made a sales agreement with Roche. Derived from info about 20% royalty.
- ·1 päivä sittenThere are some interesting posts about chemometec on the stock debate site Proinvestor.com. Here, the track with tecan is seen as a new strategic point, which they believe is overlooked by the market. How much there is to it, I find difficult to assess, but it sounds exciting. It would be interesting if someone with insight had comments on this in this chat.ChemoMetec and Roche Diagnostics have now entered into a formal agreement, which specifically includes the development of a connection kit between Roche Cedex Bio Analyzer and ChemoMetec's Xcytomatic 30 (XM30) as well as the subsequent commercialization. The important part of the agreement: It is especially these three things that I find interesting: 1. Roche designs the connection kit Roche is responsible for design as well as verification & validation. 2. They will actively market the solution together Roche and ChemoMetec have committed to a joint go-to-market strategy. They will actively co-promote the combined solution to both existing and potential customers. 3. Both retain their own sales channels Roche continues to sell Cedex Bio. ChemoMetec continues to sell XM30. This means that the agreement is not just about integration — it attempts to create a unified commercial workflow where both companies can achieve more sales. In my assessment, this is significantly more interesting than an ordinary technical integration. The potential value chain becomes: Roche Cedex Bio + ChemoMetec XM30 ↓ integrated hardware/software ↓ validated solution ↓ joint go-to-market ↓ Roche + ChemoMetec expose the solution to their existing pharma/biotech customers ↓ more XM30 installations ↓ more recurring consumables So a Roche-driven acceleration of XM30 installations can have a multiplier effect: More instruments → larger installed base → more recurring consumables → higher and more predictable revenue. And when Roche simultaneously actively co-promotes the solution, ChemoMetec gains access to a sales engine that is enormously much larger than ChemoMetec's own organization.
- ·1 päivä sittenIt looks like there's a lot of resistance when it approaches 500. I think it will gain momentum when it breaks through.Probably just a matter of short time before 500 is broken :) SEB's hold recommendation does not seem to stop the upward trend :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt